26 results on '"Abrignani S"'
Search Results
2. The combination of IFN-lambda-4 and HLA-DPB1 polymorphisms accurately predict HBsAg loss in IFN treated genotype D HBeAg-negative patients with chronic hepatitis B
3. O113 : HLA DPB1 rs9277535 polymorphism strongly predicts HBsAg clearance in IFN treated genotype D HBeAg-negative patients with chronic hepatitis B
4. HLA DPB1 rs9277535 polymorphism strongly predicts HBsAg clearance in interferon treated genotype D HBeAg-negative patients with chronic hepatitis B
5. Why is it so difficult to develop a hepatitis C virus preventive vaccine?
6. P.02.11 PHENOTYPIC AND FUNCTIONAL CHARACTERIZATION OF INFLAMMATORY CELL INFILTRATE IN ADULT-ONSET AUTOIMMUNE ENTEROPATHY AND ITS EVOLUTION WITH GLUCOCORTICOIDS
7. The CD4-centered universe of human T cell subsets
8. P.05.9 PHENOTYPIC AND FUNCTIONAL CHARACTERIZATION OF INTRAEPITHELIAL AND LAMINA PROPRIA INFLAMMATORY CELL INFILTRATE IN AUTOIMMUNE ENTEROPATHY
9. OC.06.1 INFLIXIMAB-INDUCED MUCOSAL HEALING ASSOCIATES WITH A DOWN-REGULATION OF IL23/TH17 IN INFLAMMATORY BOWEL DISEASES
10. CS15-7. Decrease of IL-17 and Gm-Csf in Intestinal Mucosa of Ibd Patients is Associated With Reduction of CD68+ Macrophages and Clinical Remission in Response to Anti-TNF Therapy
11. P.1.14: INFLIXIMAB MODULATES IL23-TH17 AXIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
12. 1318 FIBROSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C IS NOT INFLUENCED BY IL28B POLYMORPHISMS
13. OC.09.6: GENETIC VARIATION IN IL28B POLYMORPHISM MAY PREDICT HBSAG CLEARANCE IN GENOTYPE D, HBEAG NEGATIVE PATIENTS TREATED WITH INTERFERON ALFA
14. 1148 THE PRESENCE OF HEPATITIS C VIRUS DELETION MUTANTS IN CHRONIC HEPATITIS C PATIENTS AND THEIR ROLE DURING PEG-IFN/RIBAVIRIN THERAPY IN HCV-1 PATIENTS
15. T-36 Fibrosis progression in patients with chronic hepatitis C is not influenced by IL28B polymorphisms
16. T-37 Distribution of the IL28B rs12979860 polymorphism and its influence on sustained virological response rates in the MIST trial
17. OC-9 The presence of hepatitis C virus deletion mutants in chronic hepatitis C patients and their role during PEG-IFN/ribavirin therapy
18. OC-2 Genetic variation in IL28B polymorphism may predict HBsAg clearance in genotype D, HBeAg negative patients treated with interferon alfa
19. P.62 INFLIXIMAB MODULATES MUCOSAL CYTOKINE PROFILE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
20. 602 THE CANDIDATE HCV E1E2MF59 VACCINE IS SAFE IN CHRONIC HEPATITIS C PATIENTS AND ACCELLERATES THE SECOND PHASE VIRAL DECLINE UPON PRIMARY RESPONSE TO PEG-INTERFERON-2A/RIBAVIRIN THERAPY
21. The candidate HCV E1E2MF59 vaccine enhances 2nd phase viral decline in responders to PEG-IFN/ribavirin
22. Corrigendum to “Chlamydia pneumoniae genome sequence analysis and identification of HLA-A2-restricted CD8(+) T cell epitopes recognized by infection-primed T cells” [Vaccine 23 (2005) 5028–5037]
23. 61 BCR-independent activation of naive B cell via CD81: Possible pathogenic mechanism of HCV associated B-lymphocyte disorders
24. Molecular analysis of VHI+ B lymphocytes in hepatitis C patients
25. Perspectives for a hepatitis C virus vaccine
26. Nonneutralizing Human Antibody Fragments against Hepatitis C Virus E2 Glycoprotein Modulate Neutralization of Binding Activity of Human Recombinant Fabs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.